Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis After Treatment with Direct Acting Antiviral Therapy | ||||
| Benha Journal of Applied Sciences | ||||
| Article 37, Volume 6, Issue 4, August 2021, Page 243-248 PDF (354.16 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2021.191466 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| M.S. El-Kady; N.E. El-Toukhy; M.S. Abd El-Wahhab | ||||
| Hepatology, Gastroenterology and Infectious Diseases, , Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Aim: this study aimed to clarify the possible effect of direct acting antivirals (DAAs) treatment on development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) cirrhotic patients. , Methods: this study was conducted on 400 chronic hepatitis C cirrhotic patients, divided into two groups according to treatment with DAAs, group I including (200 Patients with chronic HCV cirrhosis treated with DAAs), and group II including (200 patients with chronic HCV cirrhosis without DAAs treatment), all patients were recruited from the Gastroenterology and Hepatology department Kobry Elkobba Military Hospital, all patients were males with no previous history of HCC, human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection or history of liver transplantation. After one year of follow up all patients were divided into further two subgroups according HCC development, group III ( 11 HCV cirrhotic patients treated with DAAs (sofosbuvir and daclatasvir) and developed HCC) and group IV (22 HCV cirrhotic patients not treated and developed HCC). Results: HCC developed more in not treated group with a significant difference as 11% of not treated group developed HCC compared to 5.5% only of treated group (P=0.046). using univariate cox regression, it was shown that no treatment was an independent risk factor of getting hepatocellular carcinoma (HCC), as cases not receiving the study treatment are at higher risk for developing HCC (HR=3.4, P=0.002). conclusion: DAA treatment is not associated with a higher risk of HCC in cirrhotic patients with chronic HCV infection in the short-term. The occurrence of HCC is significantly decreased in patients treated with DAAs. | ||||
| Keywords | ||||
| Hepatocellular Carcinoma; Hepatitis C; Direct Acting Antiviral; DAAs; HCC | ||||
|
Statistics Article View: 95 PDF Download: 258 |
||||
